Abstract

Colchicine is the primary treatment for familial Mediterranean fever (FMF); however, colchicine resistance poses a major challenge, affecting about 5–10% of patients. This study aimed to compare colchicine-response and colchicine-resistant patients and identify predictors of resistance. A retrospective analysis was performed in a tertiary rheumatology clinic. FMF patients (≥18 years) diagnosed per Tel-Hashomer criteria, on colchicine ≥6 months, compliant per the modified Morisky scale, with exon 10 mutations and complete data were included. Colchicine resistance was defined as ≥1 episode/month for >3 months despite maximum tolerated colchicine doses. Comparative analyses were performed. The study included 123 colchicine-response (65.9% female, median age 39) and 64 colchicine-resistant patients (62.5% female, median age 31.5). Colchicine-resistant patients were younger at diagnosis and symptom onset (p

Key words: FMF, colchicine resistance, predictive, adult